19 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
, or require us to discontinue clinical trials altogether;
delays in necessary interactions with regulators (including the FDA), ethics committees … of Conduct and Business Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
(including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or furlough … result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Business Ethics, but it is not always possible
424B5
mgjr pbdmle8
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
qnjss
8 May 23
Prospectus supplement for primary offering
5:18pm
DEF 14A
qcfoioq o6d4r6b
25 Nov 22
Definitive proxy
6:16am
424B5
eze9ep1 i67w9
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
efprzq7jn unt1ly
8 Nov 22
Quarterly report
4:09pm
424B5
j28yz0me88ah6wcrv
21 Oct 22
Prospectus supplement for primary offering
4:16pm
424B5
iylt5rxzdkjfm
13 Oct 22
Prospectus supplement for primary offering
4:56pm
8-K12B
wcdgf a3nf
13 Oct 22
Notification of registration of securities
7:24am
8-K12B
EX-14.1
83p zksn0wijgx7
13 Oct 22
Notification of registration of securities
7:24am
- Prev
- 1
- Next